Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Inhibrx Inc (INBX) USD0.0001

Sell:$36.54 Buy:$36.99 Change: $0.43 (1.18%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.43 (1.18%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.43 (1.18%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inhibrx Inc. is a clinical-stage biotechnology company. The Company is focused on developing biologic therapeutics for people with life-threatening conditions. It has a pipeline of novel biologic therapeutic candidates, developed using its single domain antibody (sdAb) platform. Its pipeline includes INBRX-109, INBRX-106, INBRX-105 and INBRX-101. INBRX-109 is a tetravalent death receptor 5 (DR5) agonist being evaluated in patients diagnosed with chondrosarcoma and mesothelioma cancers. INBRX-106 is a hexavalent OX40 agonist being investigated in patients with locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered tetravalent sdAb based therapeutic candidate, acting both as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB. INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein therapeutic candidate, in development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Contact details

11025 N. Torrey Pines Road, Suite 200
United States
+1 (858) 7954220

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.37 billion
Shares in issue:
37.89 million
United States
US dollar

Key personnel

  • Mark Lappe
    Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Brendan Eckelman
    Co-Founder, Executive Vice President - Corporate Strategy, Chief Scientific Officer
  • Kelly Deck
    Chief Financial Officer
  • Klaus Wagner
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.